UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFR signaling.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
22 04 2021
Historique:
received: 12 03 2021
accepted: 20 04 2021
pubmed: 23 4 2021
medline: 28 10 2021
entrez: 22 4 2021
Statut: epublish

Résumé

To adapt in an ever-changing environment, cells must integrate physical and chemical signals and translate them into biological meaningful information through complex signaling pathways. By combining lipidomic and proteomic approaches with functional analysis, we have shown that ubiquitin domain-containing protein 1 (UBTD1) plays a crucial role in both the epidermal growth factor receptor (EGFR) self-phosphorylation and its lysosomal degradation. On the one hand, by modulating the cellular level of ceramides through N-acylsphingosine amidohydrolase 1 (ASAH1) ubiquitination, UBTD1 controls the ligand-independent phosphorylation of EGFR. On the other hand, UBTD1, via the ubiquitination of Sequestosome 1 (SQSTM1/p62) by RNF26 and endolysosome positioning, participates in the lysosomal degradation of EGFR. The coordination of these two ubiquitin-dependent processes contributes to the control of the duration of the EGFR signal. Moreover, we showed that UBTD1 depletion exacerbates EGFR signaling and induces cell proliferation emphasizing a hitherto unknown function of UBTD1 in EGFR-driven human cell proliferation.

Identifiants

pubmed: 33884955
doi: 10.7554/eLife.68348
pii: 68348
pmc: PMC8118655
doi:
pii:

Substances chimiques

Ceramides 0
Neoplasm Proteins 0
RNF26 protein, human 0
SQSTM1 protein, human 0
Sequestosome-1 Protein 0
UBTD1 protein, human 0
Ubiquitins 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
ASAH1 protein, human EC 3.5.1.23
Acid Ceramidase EC 3.5.1.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021, Torrino et al.

Déclaration de conflit d'intérêts

ST, VT, BD, MD, CH, LB, SD, JU, MI, AG, LF, DD, SL, MC, TB, FB, JG, SC No competing interests declared

Références

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9044-8
pubmed: 21571640
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30
pubmed: 18272501
Nat Rev Mol Cell Biol. 2018 Jan;19(1):59-70
pubmed: 28928488
Nature. 1995 Nov 23;378(6555):416-9
pubmed: 7477383
Annu Rev Biochem. 2012;81:203-29
pubmed: 22524316
Exp Cell Res. 2000 Apr 10;256(1):74-82
pubmed: 10739654
J Biol Chem. 1986 Feb 15;261(5):2434-40
pubmed: 2418024
Nat Rev Mol Cell Biol. 2011 Feb;12(2):104-17
pubmed: 21252999
J Pathol. 2015 Mar;235(4):656-67
pubmed: 25382750
BMC Biotechnol. 2007 Nov 30;7:85
pubmed: 18053131
J Cell Sci. 2017 Dec 15;130(24):4087-4096
pubmed: 29180516
Int J Mass Spectrom. 2011 Aug 15;305(2-3):138-150
pubmed: 21860602
Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
pubmed: 10404636
Prog Mol Subcell Biol. 2018;57:235-272
pubmed: 30097778
Biochim Biophys Acta. 2016 Sep;1862(9):1459-71
pubmed: 27155573
Theranostics. 2020 Apr 27;10(13):5790-5801
pubmed: 32483419
EMBO Rep. 2019 Apr;20(4):
pubmed: 30804013
Nature. 2012 May 23;485(7399):465-70
pubmed: 22622570
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Biochem Biophys Res Commun. 2014 Jan 3;443(1):7-12
pubmed: 24211586
J Cell Biol. 1996 Mar;132(6):1011-23
pubmed: 8601581
Annu Rev Cell Dev Biol. 2006;22:159-80
pubmed: 16753028
J Cell Sci. 2016 Dec 1;129(23):4329-4339
pubmed: 27799357
Nat Biotechnol. 2013 Jul;31(7):638-46
pubmed: 23792630
Cell. 2016 Jun 30;166(1):152-66
pubmed: 27368102
J Proteome Res. 2015 Feb 6;14(2):953-66
pubmed: 25476789
Bio Protoc. 2017 Oct 5;7(19):
pubmed: 29082291
Nature. 2010 Mar 11;464(7286):243-9
pubmed: 20190736
Nat Rev Mol Cell Biol. 2009 May;10(5):319-31
pubmed: 19352404
J Biochem. 2015 Oct;158(4):309-19
pubmed: 25888580
Nat Rev Cancer. 2012 Jul 12;12(8):553-63
pubmed: 22785351
Science. 2011 May 6;332(6030):680-6
pubmed: 21551057
Mol Cell. 2003 Feb;11(2):507-17
pubmed: 12620237
Nat Rev Mol Cell Biol. 2009 Nov;10(11):755-64
pubmed: 19851334
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Nucleic Acids Res. 2011 Jan;39(Database issue):D561-8
pubmed: 21045058
Dev Cell. 2011 Nov 15;21(5):959-65
pubmed: 22036506
Traffic. 2012 Feb;13(2):329-37
pubmed: 22017370
Nat Commun. 2018 Apr 24;9(1):1621
pubmed: 29692406
Biochim Biophys Acta Gen Subj. 2020 Oct;1864(10):129650
pubmed: 32522525
Cell Res. 2009 Jan;19(1):58-70
pubmed: 19050695
Nat Cell Biol. 2009 Feb;11(2):123-32
pubmed: 19136968
Nat Commun. 2011 Jan 18;2:158
pubmed: 21245839
Front Biosci. 2002 Feb 01;7:d376-89
pubmed: 11815285
Nat Cell Biol. 2016 May 27;18(6):579-86
pubmed: 27230526
Science. 2009 Nov 27;326(5957):1220-4
pubmed: 19965465
EMBO J. 2005 Oct 5;24(19):3353-9
pubmed: 16148945
J Invest Dermatol. 2006 May;126(5):954-62
pubmed: 16456534

Auteurs

Stéphanie Torrino (S)

Université Côte d'Azur, CNRS, IPMC, Valbonne, France.
Université Côte d'Azur, Inserm, C3M, Team Targeting prostate cancer cell metabolism, Nice, France.

Victor Tiroille (V)

Université Côte d'Azur, Inserm, C3M, Team Targeting prostate cancer cell metabolism, Nice, France.

Bastien Dolfi (B)

Université Côte d'Azur, Inserm, C3M, Team Metabolism and cancer, Nice, France.

Maeva Dufies (M)

Biomedical Department, Centre Scientifique de Monaco, Monaco, Monaco.

Charlotte Hinault (C)

Université Côte d'Azur, Inserm, C3M, Team Targeting prostate cancer cell metabolism, Nice, France.
Biochemistry Laboratory, University Hospital, Nice, France.

Laurent Bonesso (L)

Biochemistry Laboratory, University Hospital, Nice, France.

Sonia Dagnino (S)

MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial CollegeLondon, London, United Kingdom.

Jennifer Uhler (J)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.

Marie Irondelle (M)

Inserm U1065, Université Côte d'Azur, Nice, France.

Anne-Sophie Gay (AS)

Université Côte d'Azur, CNRS, IPMC, Valbonne, France.

Lucile Fleuriot (L)

Université Côte d'Azur, CNRS, IPMC, Valbonne, France.

Delphine Debayle (D)

Université Côte d'Azur, CNRS, IPMC, Valbonne, France.

Sandra Lacas-Gervais (S)

CCMA, UFR Sciences, Université Côte d'Azur, Nice, France.

Mireille Cormont (M)

Université Côte d'Azur, Inserm, C3M, Team Cellular and Molecular Pathophysiology of Obesity and Diabetes, Nice, France.

Thomas Bertero (T)

Université Côte d'Azur, CNRS, IPMC, Valbonne, France.

Frederic Bost (F)

Université Côte d'Azur, Inserm, C3M, Team Targeting prostate cancer cell metabolism, Nice, France.

Jerome Gilleron (J)

Université Côte d'Azur, Inserm, C3M, Team Cellular and Molecular Pathophysiology of Obesity and Diabetes, Nice, France.

Stephan Clavel (S)

Université Côte d'Azur, Inserm, C3M, Team Targeting prostate cancer cell metabolism, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH